|Title||Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Farinholt, T, Doddapaneni, H, Qin, X, Menon, V, Meng, Q, Metcalf, G, Chao, H, Gingras, M-C, Avadhanula, V, Farinholt, P, Agrawal, C, Muzny, DM, Piedra, PA, Gibbs, RA, Petrosino, J|
|Date Published||2021 Oct 01|
|Keywords||BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Humans, Immune Evasion, SARS-CoV-2|
BACKGROUND: This study aims to identify the causative strain of SARS-CoV-2 in a cluster of vaccine breakthroughs. Vaccine breakthrough by a highly transmissible SARS-CoV-2 strain is a risk to global public health.
METHODS: Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) by qPCR (quantitative polymerase chain reaction) for Wuhan-Hu1 and alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant. GATK (genome analysis toolkit) variants were filtered with allele fraction ≥80 and min read depth 30x.
RESULTS: Viral sequencing revealed an infection cluster of 6 vaccinated patients infected with the delta (B.1.617.2) SARS-CoV-2 variant. With no history of vaccine breakthrough, this suggests the delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.
CONCLUSIONS: Delta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with previously described increased transmissibility over alpha variant and now, possible vaccine breakthrough.
FUNDING: Parts of this work was supported by the National Institute of Allergy and Infectious Diseases (1U19AI144297) and Baylor College of Medicine internal funding.
|Alternate Journal||BMC Med|
|PubMed Central ID||PMC8483940|
|Grant List||U19 AI144297 / AI / NIAID NIH HHS / United States|